[go: up one dir, main page]

AR085837A1 - Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer - Google Patents

Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer

Info

Publication number
AR085837A1
AR085837A1 ARP120101128A ARP120101128A AR085837A1 AR 085837 A1 AR085837 A1 AR 085837A1 AR P120101128 A ARP120101128 A AR P120101128A AR P120101128 A ARP120101128 A AR P120101128A AR 085837 A1 AR085837 A1 AR 085837A1
Authority
AR
Argentina
Prior art keywords
disease
therapy
level
therapeutic level
alzheimer
Prior art date
Application number
ARP120101128A
Other languages
English (en)
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR085837A1 publication Critical patent/AR085837A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso del nivel de ciertas citoquinas en la sangre de un paciente como una medida objetiva con el propósito de evaluar el progreso de la enfermedad en pacientes que tienen la enfermedad de Alzheimer y con el propósito de determinar la eficacia de un régimen de tratamiento. Se proveen métodos para tratar la enfermedad de Alzheimer y controlar la eficacia terapéutica.Reivindicación 1: Un método para evaluar la eficacia de una terapia pretendida para tratar la enfermedad de Alzheimer, caracterizado porque comprende los pasos de: (a) determinar el nivel promedio de una citoquina en una muestra de sangre tomada de sujetos que sufren de la enfermedad de Alzheimer pero no reciben la terapia, para obtener de ese modo un nivel no terapéutico de la citoquina; (b) determinar el nivel promedio de la citoquina en una muestra de sangre tomada de sujetos que sufren de la enfermedad de Alzheimer y que reciben la terapia, para obtener de ese modo un nivel terapéutico de la citoquina; y (c) comparar el nivel terapéutico con el nivel no terapéutico, para determinar de ese modo la eficacia de la terapia, donde la terapia se considera efectiva cuando el nivel terapéutico es más alto que el nivel no terapéutico, y la terapia se considera inefectiva cuando el nivel terapéutico es igual o más bajo que el nivel no terapéutico, donde tanto los sujetos en (a) como los sujetos en (b) incluyen al menos 5 individuos.
ARP120101128A 2011-04-01 2012-03-30 Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer AR085837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161470819P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
AR085837A1 true AR085837A1 (es) 2013-10-30

Family

ID=46208748

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101128A AR085837A1 (es) 2011-04-01 2012-03-30 Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer

Country Status (12)

Country Link
US (1) US20120251524A1 (es)
EP (1) EP2694978A1 (es)
JP (1) JP2014513284A (es)
KR (1) KR20130143659A (es)
CN (1) CN103547924A (es)
AR (1) AR085837A1 (es)
AU (1) AU2012236137A1 (es)
BR (1) BR112013025197A2 (es)
CA (1) CA2831863A1 (es)
MX (1) MX2013011325A (es)
TW (1) TW201250247A (es)
WO (1) WO2012135752A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
PL2994160T3 (pl) * 2013-05-06 2019-10-31 Baxalta Inc Leczenie subpopulacji osób z chorobą alzheimera z użyciem połączonej immunoglobuliny g
CN105353135A (zh) * 2015-11-23 2016-02-24 中国人民解放军第三军医大学第一附属医院 阿尔茨海默病标志物的用途
CN116367846A (zh) * 2020-09-08 2023-06-30 美商生命科学有限公司 用同种异体间充质干细胞治疗阿尔茨海默病
AU2024274218A1 (en) * 2023-05-18 2025-11-06 Grifols Worldwide Operations Limited Method to determine the efficacy of a neurodegenerative disease treatment
CN119470910A (zh) * 2024-11-01 2025-02-18 安徽医科大学 一种IL-12p70蛋白在认知障碍疾病中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2411455T3 (es) * 2003-11-19 2013-07-05 Rules-Based Medicine, Inc. Procedimiento para el diagnóstico y la monitorización de la enfermedad de Alzheimer
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
GT200600065A (es) * 2005-02-14 2006-10-02 Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
US20090181008A1 (en) * 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
AU2008286361B2 (en) * 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

Also Published As

Publication number Publication date
MX2013011325A (es) 2014-07-09
BR112013025197A2 (pt) 2019-09-24
CN103547924A (zh) 2014-01-29
AU2012236137A1 (en) 2013-05-02
TW201250247A (en) 2012-12-16
WO2012135752A1 (en) 2012-10-04
CA2831863A1 (en) 2012-10-04
US20120251524A1 (en) 2012-10-04
JP2014513284A (ja) 2014-05-29
EP2694978A1 (en) 2014-02-12
KR20130143659A (ko) 2013-12-31

Similar Documents

Publication Publication Date Title
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
AR085837A1 (es) Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer
BR112015012731A2 (pt) uso de eribulina no tratamento de câncer de mama
MX2014010268A (es) Metodos, aparatos y sistemas para el diagnostico y tratamiento de trastornos del estado de animo.
WO2017062456A3 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
PH12017501253B1 (en) Method and apparatus for the measurement of autonomic function for the diagnosis and validation of patient treatments and outcomes
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
MX2023010635A (es) Método para el diagnóstico y el tratamiento de lesiones tisulares profundas a travez de mediciones de humedad subepidérmica.
MX352789B (es) Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
EP2572637A4 (en) DEVICE FOR THE EXAMINATION OF THE NERVOUS FUNCTION
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
MX348082B (es) Metodos para detectar daño cardiaco.
CL2020002047A1 (es) Métodos terapéuticos y diagnósticos para enfermedades inflamatorias mediadas por mastocitos.
EA201700123A1 (ru) Способ прогнозирования варианта лекарственного препарата для лечения депрессии
WO2013071012A3 (en) Personalized strategic cancer treatment
MX2012014720A (es) Aparato, metodo y medio de almacenamiento legible por computadora para evaluar una condición fisiológica de un paciente.
Fazli et al. Noise induced hearing loss in Zanjan dentists
RU2011122721A (ru) Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl
Karadibak et al. Effect of complex decongestive therapy on upper extremity lymphedema
YI et al. The clinical application of SA9800-based biofeedback therapy device in postpartum recovery
Dailey et al. Transcutaneous Electrical Nerve Stimulation (TENS) reduces pain and improves function in people with Fibromyalgia
CR10486A (es) Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico

Legal Events

Date Code Title Description
FB Suspension of granting procedure